CKS-17

CC(C)C[C@H](N)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@H](C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CCC(O)=O)C(NCC(NCC(N[C@H](C(O)=O)CC(C)C)=O)=O)=O)=O)=O)=O)CC1=CC=CC=C1)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O

[1]Haraguchi S, et, al. Induction of intracellular cAMP by a synthetic retroviral envelope peptide: a possible mechanism of immunopathogenesis in retroviral infections. Proc Natl Acad Sci U S A. 1995 Jun 6;92 (12) :5568-71.|[2]Nelson M, et, al. Effects of CKS-17, a synthetic retroviral envelope peptide, on cell-mediated immunity in vivo: immunosuppression, immunogenicity, and relation to immunosuppressive tumor products. Cancer Immunol Immunother. 1989;30 (2) :113-8.|[3]Nelson M, et, al. Inhibition of interleukin-2 production by tumor cell products and by CKS-17, a synthetic retroviral envelope peptide. Cancer Immunol Immunother. 1990;30 (6) :331-41.